Healthcare & Life Sciences

We have wide-ranging experience of investing in the broader Healthcare sector, including in care services, pharma services and medical products

The healthcare and life sciences market benefits from favourable demographics and constantly rising demand. We are currently backing two rapidly expanding businesses serving the global life sciences market: Random42 and Hanson Wade. Both are working with pharma and biotech companies across different continents and sizes, basing their service excellence on deep scientific expertise.

In healthcare services, we are investing in care providers with the aim of putting service excellence and the quality of outcomes at the heart of their offering. We believe that our investment will underpin high-quality care delivered through efficient and innovative operating models which can quickly gain market share. We strongly believe that businesses that can innovate and provide a higher-quality service will prosper in the long term.

High-quality outcomes for patients, service users and consumers are at the core of Graphite’s investment strategy.

We have an excellent record in the broader healthcare sector. Our realised investments have generated a return of 2.5x times cost, with no investment returning less than 1.6x cost. We have twice won the ‘Health Investor of the Year’ award.